...
首页> 外文期刊>International journal of molecular medicine >Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes
【24h】

Puerarin ameliorates hepatic steatosis by activating the PPARα and AMPK signaling pathways in hepatocytes

机译:葛根素通过激活肝细胞中的PPARα和AMPK信号通路改善肝脂肪变性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Non-alcoholic fatty liver disease (NAFLD) is characterized by the hepatic manifestation of metabolic syndrome and is the leading cause of chronic liver disease. Steatohepatitis plays a critical role in the process resulting in liver fibrosis and cirrhosis. Puerarin is a herbal product widely used in Asia, and is believed to have therapeutic benefits for alleviating the symptoms of steatohepatitis. The present study was designed to investigate the effects and mechanisms of action of puerarin in reducing lipid accumulation in oleic acid (OA)-treated HepG2 cells. Hepatocytes were treated with OA with or without puerarin to observe lipid accumulation by Oil?Red?O staining. We also examined hepatic lipid contents (e.g., triacylglycerol and cholesterol) following treatment with puerarin. Western blot analysis and reverse transcription-polymerase chain reaction (RT-PCR) were used to measure sterol regulatory element binding protein (SREBP)-1, fatty acid synthase?(FAS), peroxisome proliferator-activated receptor?α (PPARα) and adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) protein and mRNA expression, respectively. Our results revealed that puerarin suppressed OA-induced lipid accumulation, and reduced the triacylglycerol and cholesterol levels. Furthermore, puerarin decreased the expression levels of lipogenic enzymes, such as FAS and SREBPs, and increased the expression levels of PPARα, which are critical regulators of hepatic lipid metabolism through the AMPK signaling pathway. These results indicate that puerarin has the same ability to activate AMPK, and reduce SREBP-1 and FAS expression, thus inhibiting hepatic lipogenesis and increasing hepatic antioxidant activity. We found that puerarin exerted a regulatory effect on lipid accumulation by decreasing lipogenesis in hepatocytes. Therefore, puerarin extract may have therapeutic benefits in the treatment of fatty liver and lipid-related metabolic disorders.
机译:非酒精性脂肪肝疾病(NAFLD)的特征是代谢综合征的肝脏表现,并且是慢性肝病的主要原因。脂肪性肝炎在导致肝纤维化和肝硬化的过程中起着至关重要的作用。葛根素是一种在亚洲广泛使用的草药产品,据信对减轻脂肪性肝炎的症状具有治疗作用。本研究旨在研究葛根素在减少油酸(OA)处理的HepG2细胞中脂质蓄积中的作用及其作用机理。肝细胞在有或没有葛根素的情况下用OA处理,通过油-红-氧染色观察脂质的积累。我们还检查了葛根素治疗后的肝脂质含量(例如,三酰基甘油和胆固醇)。使用蛋白质印迹分析和逆转录聚合酶链反应(RT-PCR)测量固醇调节元件结合蛋白(SREBP)-1,脂肪酸合酶?(FAS),过氧化物酶体增殖物激活受体?α(PPARα)和腺苷5'-单磷酸(AMP)激活的蛋白激酶(AMPK)蛋白质和mRNA表达。我们的结果表明,葛根素抑制了OA诱导的脂质蓄积,并降低了三酰甘油和胆固醇水平。此外,葛根素降低了脂肪生成酶(如FAS和SREBPs)的表达水平,并增加了PPARα的表达水平,PPARα是通过AMPK信号通路对肝脏脂质代谢的关键调节剂。这些结果表明,葛根素具有相同的激活AMPK的能力,并降低SREBP-1和FAS的表达,从而抑制了肝脏的脂肪生成并增加了肝脏的抗氧化活性。我们发现葛根素通过减少肝细胞脂肪生成对脂质蓄积发挥调节作用。因此,葛根素提取物在治疗脂肪肝和脂质相关的代谢性疾病中可能具有治疗益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号